Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07053033
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Brain Metastases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Surgery — PROCEDUREParticipants will initially undergo craniotomy and surgical resection of lesions or LITT
- LITT — PROCEDUREParticipants will undergo 4-core stereotactic biopsy and LITT by experienced neurosurgeons with specific expertise.
Study Details
standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).
Key Dates
- Start date
- Jan 1, 2026
- Status verified
- Mar 2026
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2028
Study Design
- Enrollment
- 155 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Eligible for surgery or LITT-SurveillancePatients will be randomized in a 1:1 manner to close surveillance versus SRS2.
- Experimental: Eligible for surgery or LITT-SRS2Patients will be randomized in a 1:1 manner to close surveillance versus SRS2.
- Experimental: Ineligible for surgery or LITT-SRS2Patients will be randomized in a 1:1 manner to close surveillance versus SRS2.
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Subha Perni, MD713-563-2543
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas M. D. Anderson Cancer Center | Houston | Texas | 77030 | Subha Perni, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
Related Studies
- Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)Recruiting · Universitaire Ziekenhuizen KU Leuven · Houston, Texas
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas